Patient characteristics
| Patient characteristics . | No. of patients . |
|---|---|
| Sex (male/female) | 17/10 |
| Median age, y (range) | 39 (16-53) |
| Diagnostic indication for SCT | |
| Acute myelogenous leukemia | 9 |
| Acute lymphoblastic leukemia | 3 |
| Chronic myeloid leukemia | 5 |
| Chronic lymphocytic leukemia | 1 |
| Non-Hodgkin lymphoma | 2 |
| Multiple myeloma | 5 |
| Hodgkin disease | 1 |
| Severe aplastic anemia | 1 |
| Risk status (standard/high) | 11/16 |
| Stem cell donor type (sibling/unrelated) | 20/7 |
| Stem cell source (bone marrow/peripheral blood) | 18/9 |
| Median no. of cells grafted (range) | |
| Mononuclear cells × 107/kg | 1.0 (0.2-0.0) |
| CFU-GM × 104/kg | 26.0 (4.3-128.4) |
| CD3+ T lymphocytes × 106/kg | 0.2 (0.2-6.4)* |
| CMV serology before SCT | |
| Recipient negative, SCT donor negative | 6 |
| Recipient negative, SCT donor positive | 3 |
| Recipient positive, SCT donor negative | 5 |
| Recipient positive, SCT donor positive | 13 |
| Patient characteristics . | No. of patients . |
|---|---|
| Sex (male/female) | 17/10 |
| Median age, y (range) | 39 (16-53) |
| Diagnostic indication for SCT | |
| Acute myelogenous leukemia | 9 |
| Acute lymphoblastic leukemia | 3 |
| Chronic myeloid leukemia | 5 |
| Chronic lymphocytic leukemia | 1 |
| Non-Hodgkin lymphoma | 2 |
| Multiple myeloma | 5 |
| Hodgkin disease | 1 |
| Severe aplastic anemia | 1 |
| Risk status (standard/high) | 11/16 |
| Stem cell donor type (sibling/unrelated) | 20/7 |
| Stem cell source (bone marrow/peripheral blood) | 18/9 |
| Median no. of cells grafted (range) | |
| Mononuclear cells × 107/kg | 1.0 (0.2-0.0) |
| CFU-GM × 104/kg | 26.0 (4.3-128.4) |
| CD3+ T lymphocytes × 106/kg | 0.2 (0.2-6.4)* |
| CMV serology before SCT | |
| Recipient negative, SCT donor negative | 6 |
| Recipient negative, SCT donor positive | 3 |
| Recipient positive, SCT donor negative | 5 |
| Recipient positive, SCT donor positive | 13 |
SCT, stem cell transplant; CFU-GM, granulocyte-macrophage colony-forming unit; CMV, cytomegalovirus.
Sheep erythrocyte rosetting resulted in incomplete removal of the T lymphocytes in 2 patients (patients 1 and 6 in Table 3), who, as a result, received 6.4 and 1.6 × 106 T cells/kg. These patients received methotrexate as additional graft-versus-host disease prophylaxis on days 1, 3, 6, and 11 after SCT.